Azimilide

Published

dm+d

Unassigned

New Medicines

Cardiovascular disorders; in patients with an implantable cardioverter defibrillator

Information

Licence extension / variation
Forest Labs
Forest Labs

Development and Regulatory status

None
None
Suspended
Mar 15: development appears to have stopped [1]

Category

Potassium channel antagonist
Cardiovascular disorders; in patients with an implantable cardioverter defibrillator
Oral

Trial or other data

Mar 15: Forest Laboratories terminated the SHIELD-2 phase III registrational trial in May 2013 (NCT01464476); no reasons were provided. The trial was required for US FDA approval of azimilide in ventricular arrhythmias; at the time of termination 240 patients had been enrolled. [1]